Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030

Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030

Strides partners with Incepta to expand women's health access with WHO-prequalified contraceptive

Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training

Merck KGaA to acquire chromatography business of JSR Life Sciences

Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions

Syngene International invests in peptide laboratory in Bengaluru

Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services

IPP organizes panel discussion on "challenges and opportunities in Indian pharma sector" in Hyderabad on Oct. 15

Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India

IPP organizes session on "Combating Heat Exchanger Tube Corrosion in Pharma and Chemical Industry" on October 15 at Sheraton Hyderabad Hotel

Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post

Integris Medtech files DRHP with SEBI for IPO

The company plans to use the funds raised from the net proceeds to repay or prepay certain loans

FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL

Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older

FDA supports new ANDA prioritization pilot to support US generic drugs

India invites applications under PRIP scheme to drive pharma-medtech innovation

Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance